2.5mg semaglutide to tirzepatide vs Semaglutide: What's the Difference? Tirzepatide vs Semaglutide 2026: 22%

In 2021, semaglutide was approved, and Wegovy was available to patients as a once-weekly injectable to treat obesity

Patients with a history of pancreatitis should use caution, and those with severe gastrointestinal disease (such as gastroparesis) may not tolerate the medication well due to its effects on gastric emptying

By activating both pathways, a dual agonist can produce a more powerful effect on appetite suppression and metabolic function than a GLP-1 agonist alone

Grayson, known as The Godmother of Pharmacology, explained how these drugs increased the risk of gallstone formation

It comes in two FDA-approved forms, both weekly injections: Mounjaro: type 2 diabetes (2.5 to 15 mg) Zepbound: obesity (2.5 to 15 mg) and moderate-to-severe obstructive sleep apnea in adults with obesity (approved December 2024) No oral tirzepatide exists as of April 2026